Cargando…
Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes
BACKGROUND: Type I interferons (IFNs) exhibit direct antiviral effects, but also distinct immunomodulatory properties. In this study, we analyzed type I IFN subtypes for their effect on prophylactic adenovirus-based anti-retroviral vaccination of mice against Friend retrovirus (FV) or HIV. RESULTS:...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193818/ https://www.ncbi.nlm.nih.gov/pubmed/21943056 http://dx.doi.org/10.1186/1742-4690-8-75 |
_version_ | 1782213892093509632 |
---|---|
author | Bayer, Wibke Lietz, Ruth Ontikatze, Teona Johrden, Lena Tenbusch, Matthias Nabi, Ghulam Schimmer, Simone Groitl, Peter Wolf, Hans Berry, Cassandra M Überla, Klaus Dittmer, Ulf Wildner, Oliver |
author_facet | Bayer, Wibke Lietz, Ruth Ontikatze, Teona Johrden, Lena Tenbusch, Matthias Nabi, Ghulam Schimmer, Simone Groitl, Peter Wolf, Hans Berry, Cassandra M Überla, Klaus Dittmer, Ulf Wildner, Oliver |
author_sort | Bayer, Wibke |
collection | PubMed |
description | BACKGROUND: Type I interferons (IFNs) exhibit direct antiviral effects, but also distinct immunomodulatory properties. In this study, we analyzed type I IFN subtypes for their effect on prophylactic adenovirus-based anti-retroviral vaccination of mice against Friend retrovirus (FV) or HIV. RESULTS: Mice were vaccinated with adenoviral vectors encoding FV Env and Gag proteins alone or in combination with vectors encoding IFNα1, IFNα2, IFNα4, IFNα5, IFNα6, IFNα9 or IFNβ. Only the co-administration of adenoviral vectors encoding IFNα2, IFNα4, IFNα6 and IFNα9 resulted in strongly improved immune protection of vaccinated mice from subsequent FV challenge infection with high control over FV-induced splenomegaly and reduced viral loads. The level of protection correlated with augmented virus-specific CD4(+ )T cell responses and enhanced antibody titers. Similar results were obtained when mice were vaccinated against HIV with adenoviral vectors encoding HIV Env and Gag-Pol in combination with various type I IFN encoding vectors. Here mainly CD4(+ )T cell responses were enhanced by IFNα subtypes. CONCLUSIONS: Our results indicate that certain IFNα subtypes have the potential to improve the protective effect of adenovirus-based vaccines against retroviruses. This correlated with augmented virus-specific CD4(+ )T cell and antibody responses. Thus, co-expression of select type I IFNs may be a valuable tool for the development of anti-retroviral vaccines. |
format | Online Article Text |
id | pubmed-3193818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31938182011-10-16 Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes Bayer, Wibke Lietz, Ruth Ontikatze, Teona Johrden, Lena Tenbusch, Matthias Nabi, Ghulam Schimmer, Simone Groitl, Peter Wolf, Hans Berry, Cassandra M Überla, Klaus Dittmer, Ulf Wildner, Oliver Retrovirology Research BACKGROUND: Type I interferons (IFNs) exhibit direct antiviral effects, but also distinct immunomodulatory properties. In this study, we analyzed type I IFN subtypes for their effect on prophylactic adenovirus-based anti-retroviral vaccination of mice against Friend retrovirus (FV) or HIV. RESULTS: Mice were vaccinated with adenoviral vectors encoding FV Env and Gag proteins alone or in combination with vectors encoding IFNα1, IFNα2, IFNα4, IFNα5, IFNα6, IFNα9 or IFNβ. Only the co-administration of adenoviral vectors encoding IFNα2, IFNα4, IFNα6 and IFNα9 resulted in strongly improved immune protection of vaccinated mice from subsequent FV challenge infection with high control over FV-induced splenomegaly and reduced viral loads. The level of protection correlated with augmented virus-specific CD4(+ )T cell responses and enhanced antibody titers. Similar results were obtained when mice were vaccinated against HIV with adenoviral vectors encoding HIV Env and Gag-Pol in combination with various type I IFN encoding vectors. Here mainly CD4(+ )T cell responses were enhanced by IFNα subtypes. CONCLUSIONS: Our results indicate that certain IFNα subtypes have the potential to improve the protective effect of adenovirus-based vaccines against retroviruses. This correlated with augmented virus-specific CD4(+ )T cell and antibody responses. Thus, co-expression of select type I IFNs may be a valuable tool for the development of anti-retroviral vaccines. BioMed Central 2011-09-26 /pmc/articles/PMC3193818/ /pubmed/21943056 http://dx.doi.org/10.1186/1742-4690-8-75 Text en Copyright © 2011 Bayer et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Bayer, Wibke Lietz, Ruth Ontikatze, Teona Johrden, Lena Tenbusch, Matthias Nabi, Ghulam Schimmer, Simone Groitl, Peter Wolf, Hans Berry, Cassandra M Überla, Klaus Dittmer, Ulf Wildner, Oliver Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes |
title | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes |
title_full | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes |
title_fullStr | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes |
title_full_unstemmed | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes |
title_short | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes |
title_sort | improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type i interferon subtypes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193818/ https://www.ncbi.nlm.nih.gov/pubmed/21943056 http://dx.doi.org/10.1186/1742-4690-8-75 |
work_keys_str_mv | AT bayerwibke improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT lietzruth improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT ontikatzeteona improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT johrdenlena improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT tenbuschmatthias improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT nabighulam improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT schimmersimone improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT groitlpeter improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT wolfhans improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT berrycassandram improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT uberlaklaus improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT dittmerulf improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes AT wildneroliver improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes |